AstraZeneca’s Voydeya Receives the US FDA’s Approval as an Add-on Therapy to Treat Extravascular Haemolysis in PNH Patients
Shots:
- The US FDA has approved Voydeya as an add-on therapy to ravulizumab or eculizumab for treating extravascular haemolysis (EVH) in adults having paroxysmal nocturnal haemoglobinuria (PNH)
- The approval was supported by the P-III (ALPHA) study investigating the safety and efficacy of Voydeya as an add-on treatment to ravulizumab or eculizumab in PNH patients experiencing EVH
- The study, at wk.12, showed a change in haemoglobin of 2.94g/dL vs 0.50g/dL from baseline, 59.5% vs 0% of patients had improved haemoglobin of ≥2 g/dL in the absence of transfusion, improvement in transfusion avoidance as well as change in FACIT-Fatigue score. Results were published in The Lancet Haematology
Ref: AstraZeneca | Image: AstraZeneca
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
